DELTACORTENE 5 mg compresse

DRUG2 trials

Sponsors

Bayer Consumer Care AG, Bayer AG, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Conditions

metastatic castrate resistant prostate cancer (mCRPC)metastatic castration resistant prostate cancer (mCRPC)symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

Phase 2

Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)

RecruitingCTIS2024-511660-89-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)

Start: 2017-06-09Target: 70Updated: 2025-06-06

Phase 4

(20510) A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH

Active, not recruitingCTIS2023-505830-89-00

Bayer Consumer Care AG, Bayer AGmetastatic castrate resistant prostate cancer (mCRPC)

Start: 2020-08-05Target: 514Updated: 2025-10-07